Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
GVHDS
MCID: GRF003
MIFTS: 65

Graft-Versus-Host Disease (GVHDS)

Categories: Blood diseases, Genetic diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Graft-Versus-Host Disease

About this section

MalaCards integrated aliases for Graft-Versus-Host Disease:

Name: Graft-Versus-Host Disease 57 11 53 36 75 33
Graft Versus Host Disease 11 58 75 53
Graft-Versus-Host Disease, Susceptibility to 57 28 38
Graft-Versus-Host Disease, Protection Against 57
Graft-Versus-Host Reaction or Disease 33
Gvhd - [graft-Versus-Host Disease] 33
Gvh - [graft-Versus-Host] Reaction 33
Gvh - [graft-Versus-Host] Disease 33
Graft Vs Host Disease 43
Graft-Vs-Host Disease 71
Gvhds 57
Gvhd 11
Gvh 58

Characteristics:


Prevelance:

Graft Versus Host Disease: 1-9/100000 (Europe) 58

Age Of Onset:

Graft Versus Host Disease: All ages 58

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Immune diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32
ICD11: 33
Orphanet: 58  
Rare immunological diseases


Sources

Summaries for Graft-Versus-Host Disease

About this section

OMIM®: 57 Transplantation of hematopoietic stem cells is a successful therapy for some tumors derived from bone marrow precursors, such as certain leukemias and lymphomas, and it can be used to cure some primary immunodeficiencies and inherited hematopoietic stem-cell diseases. One of the major complications of allogeneic bone marrow transplantation is graft-versus-host disease (GVHD), in which mature donor T cells that contaminate the allogeneic bone marrow recognize the tissues of the recipient as foreign, causing a severe inflammatory disease characterized by rashes, diarrhea, and liver disease. GVHD is particularly virulent when there is a mismatch of a major major histocompatibility complex (MHC) class I or class II antigen. Most transplants are therefore undertaken only when the donor and recipient are HLA-matched sibs or, less frequently, when there is an HLA-matched unrelated donor. However, GVHD also occurs in the context of disparities between minor histocompatibility antigens, and immunosuppression must be used in every stem-cell transplant (summary by Janeway et al., 2005). At the core of the immunogenetic basis for GVHD is the diversity of HLA, killer immunoglobulin-like receptors (KIRs; see 604936), and cytokine genes. HLA class I molecules function as ligands for natural killer cell inhibitory KIRs, indicating that GVHD results from a complex interplay between innate and adaptive immune responses. Cytokines may modulate the intensity of tissue injury and inflammation in GVHD, and therefore cytokine polymorphisms in either patient or donor or both may explain individual risks of GVHD (review by Petersdorf and Malkki, 2006). (614395) (Updated 08-Dec-2022)

MalaCards based summary: Graft-Versus-Host Disease, also known as graft versus host disease, is related to bronchiolitis obliterans and acute graft versus host disease. An important gene associated with Graft-Versus-Host Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PAK Pathway. The drugs Posaconazole and Panobinostat have been mentioned in the context of this disorder. Affiliated tissues include Bone, bone marrow and t cells, and related phenotypes are elevated hepatic transaminase and skin erosion

Disease Ontology: 11 An immune system disease that is characterized by recognition by mature donor T cells, that contaminate the allogeneic bone marrow, of the recipient's tissue as foreign, causing a severe inflammatory disease characterized by rashes, diarrhea, and liver disease, and that has material basis in an associated with variation in the interleukin-10 gene (IL10) on chromosome 1q32.

Orphanet: 58 A rare disease that occurs after allogeneic hematopoietic stem cell transplant and is a reaction of donor immune cells against host tissues. Activated donor T cells damage host epithelial cells after an inflammatory cascade that begins with the preparative regimen.

Wikipedia: 75 Graft-versus-host disease (GvHD) is a syndrome, characterized by inflammation in different organs. GvHD... more...
Sources

Related Diseases for Graft-Versus-Host Disease

About this section

Diseases in the Graft-Versus-Host Disease family:

Acute Graft Versus Host Disease Chronic Graft Versus Host Disease

Diseases related to Graft-Versus-Host Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1236)
# Related Disease Score Top Affiliating Genes
1 bronchiolitis obliterans 32.4 TNF IL10 IFNG
2 acute graft versus host disease 32.2 TNF IL2 IL10 IFNG CSF3 ARHGAP45
3 systemic scleroderma 31.6 TNF IL2 IL10
4 human cytomegalovirus infection 31.5 TNF IL10
5 aplastic anemia 31.4 TNF IL10 IFNG CSF3
6 autoimmune disease 31.3 TNF IL2 IL10 IFNG
7 bronchiolitis 31.2 TNF IL2 IL10 IFNG
8 lymphopenia 31.2 IL2 IL10 IFNG
9 exanthem 31.1 TNF IL2 IL10 IFNG CSF3
10 viral infectious disease 31.1 TNF IL2 IL10 IFNG
11 alopecia 31.1 TNF IL2 IFNG
12 keratoconjunctivitis 31.1 TNF IL2 IFNG
13 lichen planus 31.1 TNF IL2 IL10 IFNG
14 hypereosinophilic syndrome 31.1 IL2 IL10 IFNG
15 leukemia, acute myeloid 31.1 TNF IL2 IL10 IFNG CSF3
16 fasciitis 31.0 TNF IL2 IFNG
17 herpes zoster 31.0 IL2 IL10 IFNG
18 enterocolitis 31.0 TNF IL10
19 severe combined immunodeficiency 30.9 TNF IL2 IL10 IFNG CSF3
20 deficiency anemia 30.9 TNF IL2 IL10 CSF3
21 primary biliary cholangitis 30.9 TNF IL2 IL10
22 hemorrhagic cystitis 30.9 TNF IL2 CSF3
23 cholangitis 30.9 TNF IL2 IL10
24 eye disease 30.8 TNF IL2 IL10 IFNG
25 dermatitis 30.8 TNF IL2 IL10 IFNG
26 blepharitis 30.8 TNF IL2
27 diarrhea 30.8 TNF IL2 IL10 IFNG CSF3
28 aspergillosis 30.8 TNF IL10 IFNG CSF3
29 t cell deficiency 30.8 IL2 IL10
30 erythema multiforme 30.8 TNF IL2 IFNG
31 invasive aspergillosis 30.7 TNF IL10 CSF3
32 conjunctivitis 30.7 TNF IL2 IL10 IFNG
33 scleritis 30.7 TNF IFNG
34 intestinal perforation 30.7 TNF IL10
35 pneumonia 30.7 TNF IL10 IFNG CSF3
36 colitis 30.7 TNF IL2 IL10 IFNG
37 myasthenia gravis 30.7 TNF IL2 IL10 IFNG
38 toxoplasmosis 30.6 TNF IL10 IFNG
39 immune deficiency disease 30.6 TNF IL2 IL10 IFNG
40 proteasome-associated autoinflammatory syndrome 1 30.6 TNF IL10 IFNG
41 alopecia areata 30.6 TNF IL2 IFNG
42 human immunodeficiency virus type 1 30.6 IL2 IL10 IFNG
43 combined immunodeficiency 30.6 TNF IL2 IL10 IFNG CSF3
44 autoimmune hepatitis 30.6 TNF IL10 IFNG
45 skin disease 30.6 TNF IL2 IL10 IFNG CSF3
46 pemphigoid 30.6 TNF IL2 IL10 IFNG
47 macs syndrome 30.6 TNF IL10 IFNG
48 leukemia, chronic lymphocytic 30.6 TNF IL2 IL10 CSF3
49 ileus 30.6 TNF IL10 IFNG
50 thymoma 30.5 TNF IL2 IL10 CSF3

Graphical network of the top 20 diseases related to Graft-Versus-Host Disease:



Diseases related to Graft-Versus-Host Disease
Sources

Symptoms & Phenotypes for Graft-Versus-Host Disease

About this section

Human phenotypes related to Graft-Versus-Host Disease:

58 30 (show all 42)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 elevated hepatic transaminase 58 30 Frequent (33%) Frequent (79-30%)
 HP:0002910
2 skin erosion 58 30 Frequent (33%) Frequent (79-30%)
 HP:0200041
3 diarrhea 58 30 Frequent (33%) Frequent (79-30%)
 HP:0002014
4 oral ulcer 58 30 Frequent (33%) Frequent (79-30%)
 HP:0000155
5 maculopapular exanthema 58 30 Frequent (33%) Frequent (79-30%)
 HP:0040186
6 chronic hepatitis 58 30 Frequent (33%) Frequent (79-30%)
 HP:0200123
7 stomatitis 58 30 Frequent (33%) Frequent (79-30%)
 HP:0010280
8 arthritis 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0001369
9 vomiting 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002013
10 skeletal muscle atrophy 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0003202
11 gastrointestinal inflammation 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0004386
12 irritability 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0000737
13 jaundice 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0000952
14 abdominal pain 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002027
15 limited elbow movement 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002996
16 inflammatory abnormality of the eye 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0100533
17 hyperbilirubinemia 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002904
18 tachycardia 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0001649
19 pneumonia 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002090
20 hepatosplenomegaly 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0001433
21 fasciitis 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0100537
22 myositis 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0100614
23 pulmonary infiltrates 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002113
24 hemophagocytosis 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0012156
25 scaling skin 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0040189
26 nausea 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002018
27 limited shoulder movement 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0006467
28 acute hepatitis 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0200119
29 recurrent gastroenteritis 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0031123
30 cutaneous sclerotic plaque 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0031359
31 lichenoid skin lesion 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0031452
32 elevated circulating alkaline phosphatase concentration 30 Occasional (7.5%) HP:0003155
33 failure to thrive 58 30 Very rare (1%) Very rare (<4-1%)
 HP:0001508
34 lipodystrophy 58 30 Very rare (1%) Very rare (<4-1%)
 HP:0009125
35 trismus 58 30 Very rare (1%) Very rare (<4-1%)
 HP:0000211
36 lymphadenopathy 58 30 Very rare (1%) Very rare (<4-1%)
 HP:0002716
37 dupuytren contracture 58 30 Very rare (1%) Very rare (<4-1%)
 HP:0005679
38 decreased lacrimation 58 30 Very rare (1%) Very rare (<4-1%)
 HP:0000633
39 stiff interphalangeal joints 58 30 Very rare (1%) Very rare (<4-1%)
 HP:0005198
40 recurrent infections 58 Frequent (79-30%)
41 inflammatory abnormality of the skin 58 Very frequent (99-80%)
42 elevated alkaline phosphatase 58 Occasional (29-5%)

Clinical features from OMIM®:

614395 (Updated 08-Dec-2022)

MGI Mouse Phenotypes related to Graft-Versus-Host Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 no phenotypic analysis MP:0003012 9.02 IFNG IL10 IL2 MYO1G TNF
Sources

Drugs & Therapeutics for Graft-Versus-Host Disease

About this section

Drugs for Graft-Versus-Host Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 290)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
2
Panobinostat Approved, Investigational Phase 4 404950-80-7 6918837
3
Lactitol Approved, Investigational Phase 4 585-86-4 157355
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
6 Antiprotozoal Agents Phase 4
7 Antiparasitic Agents Phase 4
8 Histone Deacetylase Inhibitors Phase 4
9 Pharmaceutical Solutions Phase 4
10 Ophthalmic Solutions Phase 4
11 Cytochrome P-450 Enzyme Inhibitors Phase 4
12 Cytochrome P-450 CYP3A Inhibitors Phase 4
13 Lubricant Eye Drops Phase 4
14 Anesthetics Phase 4
15
Hydroxyitraconazole Phase 4 108222
16
Remestemcel-L Approved, Investigational Phase 3
17
Budesonide Approved Phase 3 51333-22-3 5281004 40000 63006
18
Clobetasol Approved, Experimental, Investigational Phase 3 25122-46-7, 25122-41-2 2791 5311051 32798
19
Aldesleukin Approved Phase 3 110942-02-4
20
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
21
Hydroxychloroquine Approved Phase 3 118-42-3 3652
22
Sodium citrate Approved, Investigational Phase 3 68-04-2 23431961
23
Protein C Approved Phase 3
24
Etoposide Approved Phase 3 33419-42-0 36462
25
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
26
Venetoclax Approved, Investigational Phase 2, Phase 3 1257044-40-8 49846579
27
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
28
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
29
Adenosine Approved, Investigational Phase 3 58-61-7 60961
30
Abatacept Approved Phase 3 332348-12-6
31
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
32
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
33
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
34
Azacitidine Approved, Investigational Phase 3 320-67-2 9444
35
Everolimus Approved Phase 2, Phase 3 159351-69-6 70789204 6442177
36
Methoxsalen Approved Phase 3 298-81-7 4114
37
Carbamide peroxide Approved Phase 3 124-43-6
38
Alefacept Approved, Investigational, Withdrawn Phase 3 222535-22-0
39
Acetylcysteine Approved, Investigational Phase 3 616-91-1 581 12035
40
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
41
Cysteine Approved, Nutraceutical Phase 3 52-90-4 594 5862
42
Semustine Experimental, Investigational Phase 3 13909-09-6 5198
43 Vitamins Phase 2, Phase 3
44 Trace Elements Phase 2, Phase 3
45 Antidotes Phase 2, Phase 3
46 Micronutrients Phase 2, Phase 3
47 Hematinics Phase 2, Phase 3
48 Bronchodilator Agents Phase 3
49 gamma-Globulins Phase 3
50 Rho(D) Immune Globulin Phase 3

Interventional clinical trials:

(show top 50) (show all 887)
# Name Status NCT ID Phase Drugs
1 A Randomized,Open,Multicenter and Prospective Study of the Optimized Dose of Anti-Thymoglobuline in Haploidentical Allogeneic Stem Cell Transplantation Unknown status NCT03190733 Phase 4 ATG
2 A Comparison of PTCy-ATG and ATG Strategy in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Unknown status NCT03689465 Phase 4 ATG;CTX;Mycophenolate Mofetil;Ciclosporin A (CsA);methotrexate (MTX)
3 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Treatment: a Multi-center, Open, Randomized, Controlled Clinical Study Unknown status NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
4 A Historically-controlled, Multi-center Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule, Prograf Injection) and Methotrexate Combination Therapy for Prevention of GVHD in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor Completed NCT02660684 Phase 4 Prograf;Methotrexate;Cyclosporine
5 Evaluation of Efficacy, Safety and Tolerability of 0.05% Cyclosporine and 0.1% Tacrolimus Eye Drops in the Treatment of Chronic Ocular Graft-versus-host Disease Completed NCT05294666 Phase 4 Cyclosporine;tacrolimus
6 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Completed NCT02805946 Phase 4 posaconazole
7 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
8 Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis Completed NCT01883180 Phase 4 ATG
9 An Open-label, Concentration Controlled, Randomized, 12 Month Study of Prograf + Rapamune + Cor Completed NCT00044720 Phase 4 Rapamune
10 A Randomized, Open-label Study to Compare the Safety and Efficacy of Cyclosporine Dose Reduction With Cyclosporine Elimination in De Novo Renal Allograft Recipients Receiving Rapamune. Completed NCT00195468 Phase 4 CYCLOSPORINE
11 A Randomized, Open-label and Multicenter Trial Comparing Withdrawal of Steroids or Tacrolimus From Sirolimus-based Immunosuppressive Regimen in de Novo Renal Allograft Recipients Completed NCT00195429 Phase 4 Tacrolimus;Sirolimus;prednisone
12 A Post Marketing Surveillance Looking at Safety of Rapamune (Sirolimus) in Indian Population Undergoing de Novo Renal Transplantation. Completed NCT00195481 Phase 4 Rapamune
13 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4 daclizumab, infliximab
14 Anti-thymocyte Globulins for GVHD Prophylaxis After HLA-matched Sibling Stem Cell Transplantation in Patients at 40 Years of Age or More With Hematological Malignancies Completed NCT01856803 Phase 4 anti thymoglobulin
15 Ruxolitinib With Calcineurin and Methotrexate vs. Calcineurin Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell Transplantation Recruiting NCT04838704 Phase 4 Ruxolitinib+Calcineurin +Methotrexate;Calcineurin +Methotrexate+Mycophenolate mofetil
16 Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies Recruiting NCT02386800 Phase 4 ruxolitinib;panobinostat
17 Impact of Optimal Doses of Antithymocyte Globulin Conditioning on Graft-versus- Host Disease and Virus Reactivation in Haploidentical Hematopoietic Stem Cell Transplantation Recruiting NCT04778618 Phase 4 Antithymocyte Globulin
18 Impact of Optimal Doses of Antithymocyte Globulin Conditioning on Graft Versus-host Disease and Virus Reactivation in Haploidentical Hematopoietic Stem Cell Transplantation Recruiting NCT05166967 Phase 4 Individual Antithymocyte globulin;Antithymocyte globulin
19 A Prospective Multicenter, Single-arm Clinical Study of Anti-CD25 Monoclonal Antibody Combined With Ruxolitinib in the Treatment of Grade 3-4 Steroid-resistant Acute Graft-versus-host Disease Recruiting NCT05021276 Phase 4 Ruxolitinib
20 Ikervis for Prophylaxis of Dry Eye Disease Due to Graft vs Host Disease Post Allogeneic Haemtopoietic Stem Cell Transplant Recruiting NCT04636918 Phase 4 Cyclosporine Ophthalmic
21 ATG Used in Allogeneic Hematopoietic Stem Cell Transplantation From HLA-matched Sibling Donor as GVHD Prophylaxis Recruiting NCT04203108 Phase 4 ATG;CsA;MTX;MMF
22 Clinical Study of rATG Individualized Administration for Prevention of GVHD and Maintenance of GVL in Haploidentical Hematopoietic Stem Cell Transplantation. Recruiting NCT05634915 Phase 4 Individual ATG;ATG
23 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials. Enrolling by invitation NCT03229200 Phase 4 Ibrutinib
24 The Prophylactic Use of Topical Cyclosporine A 0.05% (Restasis) to Prevent Onset and Progression of Graft-versus-host Disease-related Dry Eye Terminated NCT00553735 Phase 4 Cyclosporine A 0.05%;Arificial Tear
25 Evaluation of Antifungal Prophylaxis Against Invasive Fungal Infections During Corticosteroid Containing Therapy for Graft-versus-host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01282879 Phase 4 Itraconazole
26 Evaluation of Dextenza in Patients With Ocular Graft Vs Host Disease (GVHD) and Effect on Ocular Surface Disease Outcomes. Withdrawn NCT04728646 Phase 4 DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use
27 Mesenchymal Stem Cells Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation Unknown status NCT02241018 Phase 2, Phase 3 CD25 monoclonal antibody;calcineurin inhibitors
28 Treatment of of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells. A Phase III Randomized Open Label Multi-center Study in Southern China. Unknown status NCT02291770 Phase 3
29 Extracorporeal Photopheresis for Steroid-refractory Acute GVHD in Children and Young Adults: a Safety and Feasibility Study. Unknown status NCT00179855 Phase 2, Phase 3
30 Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning With Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor HCT Unknown status NCT02178683 Phase 3 Tacrolimus and MMF.
31 Phase â…¡/â…¢ Clinical Trial, Multicenter, Randomized, Controlled, for the Evaluation of Efficacy and Safety of Therapy With Allogenic Mesenchymal Stem Cells in Patients With Chronic Graft Versus Host Disease Unknown status NCT01526850 Phase 2, Phase 3 Cyclosporine and Glucocorticoid
32 A Phase II Prospective Randomized Trial of Donor T-memory Cells (CD45RA Depleted) Infusion for Prevention of Infections After Allogeneic TcRαβ/CD19-depleted Hematopoietic Stem Cell Transplantation Unknown status NCT02942173 Phase 2, Phase 3
33 Treatment of Steroid-resistant Severe Acute Graft-versus-host Disease With Mesenchymal Stem Cells Unknown status NCT03631589 Phase 2, Phase 3
34 The Effect of Folinic Acid Rescue Following Methotrexate (MTX) Graft-versus-host Disease (GVHD) Prophylaxis on Regimen Related Toxicity and Transplantation Outcome: a Double Blind Randomized Controlled Study Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
35 Comparing ATG-Fresenius vs Thymoglobulin for the Prevention of Graft-versus-host Disease in the Setting of Haplo-identical Hematopoietic Stem Cell Transplantation Unknown status NCT03631563 Phase 2, Phase 3 Immunosuppressive Agent
36 A Randomized Trial of Thymoglobulin to Prevent Chronic Graft Versus Host Disease in Patients Undergoing Hematopoietic Progenitor Cell Transplantation (HPCT) From Unrelated Donors Unknown status NCT01217723 Phase 3
37 Randomized Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation Unknown status NCT00207792 Phase 3 filgrastim
38 Multi-Centre Prospective Randomized Study on the Use of Two Different Doses of Rabbit Anti-Thymocyte Globulin for GVHD Prevention in Paediatric Patients With Haematological Malignancies Given an Unrelated Donor Haematopoietic Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius
39 Safety Follow-up Through 180 Days of Treatment With Remestemcel-L in Study MSB-GVHD001 in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD Completed NCT02652130 Phase 3
40 A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD) Completed NCT02959944 Phase 3 ibrutinib;Placebo;Prednisone
41 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
42 The Use of Etanercept (Enbrel) as Sole Treatment for Grade I Acute Graft Versus Host Disease Completed NCT00726375 Phase 3 Etanercept (Enbrel)
43 A Randomized Trial of Sirolimus-Based Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation in Relapsed Acute Lymphoblastic Leukemia Completed NCT00382109 Phase 3 thiotepa;cyclophosphamide;tacrolimus;methotrexate;sirolimus
44 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
45 Phase III Trial of Hydroxychloroquine + Standard Therapy for Chronic Graft-Versus-Host Disease Completed NCT00031824 Phase 3 cyclosporine;hydroxychloroquine;prednisone;tacrolimus
46 A Phase III Study to Determine Efficacy and Safety of Low-Dose Glucocorticoids for Initial Treatment of Acute Graft-versus-Host Disease Completed NCT00929695 Phase 3 prednisone;methylprednisolone
47 GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease Completed NCT03139604 Phase 3 Itacitinib;Placebo;Prednisone;Methylprednisolone
48 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD Completed NCT00562497 Phase 3 Prochymal®
49 A Phase III, Randomized, Placebo-Controlled, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Oral Beclomethasone 17, 21-Dipropionate (BDP) in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Grade II Graft vs. Host Disease With Gastrointestinal Symptoms Completed NCT00043147 Phase 3 beclomethasone dipropionate;methylprednisolone;prednisone
50 A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802) Completed NCT01002742 Phase 3 Mycophenolate Mofetil;Placebo

Search NIH Clinical Center for Graft-Versus-Host Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Daclizumab
Methylprednisolone
methylprednisolone acetate
Methylprednisolone Sodium Succinate
Muromonab-CD3
mycophenolate mofetil
mycophenolate mofetil hydrochloride
Prednisone
PREDNISONE PWDR
Tacrolimus
Thalidomide

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Graft-Versus-Host Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Graft-Versus-Host Disease:
Bone marrow-derived mesenchymal stem cells for treatment of chronic graft vs. host disease
Bone marrow-derived mesenchymal stem cells for treatment of graft vs. host disease
FCRx, bioengineered hematopoietic stem cells for immunological tolerance
Homeo-GH, bone marrow-derived mesenchymal stem cells for treatment of graft-versus-host disease
Mesenchymal stem cells for graft vs. host disease (Case Comprehensive Cancer Center)
Mesenchymal stem cells for graft vs. host disease (CHU University Hospital Liege)
Mesenchymal stem cells for graft vs. host disease (UMC Utrecht)
Mesenchymal stromal cells for treatment of graft versus host disease
MultiStem, bone marrow-derived cells for graft vs host disease
Prochymal, mesenchymal stem cells for treatment of graft versus host disease
Promostem, mesenchymal stem cells for treatment of graft-versus-host disease
Embryonic/Adult Cultured Cells Related to Graft-Versus-Host Disease:
Bone marrow-derived mesenchymal stem cells PMIDs: 21142788 19925878
Bone marrow-derived mesenchymal stem cells (family)
Facilitating cells PMIDs: 17150368
Clonal bone marrow-derived mesenchymal stem cells (Homeo-GH) PMIDs: 18513161
Bone marrow-derived mesenchymal stromal cells PMIDs: 22183779
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 21175285 21798013 23205020

Cochrane evidence based reviews: graft vs host disease

Sources

Genetic Tests for Graft-Versus-Host Disease

About this section

Genetic tests related to Graft-Versus-Host Disease:

# Genetic test Affiliating Genes
1 Graft-Versus-Host Disease, Susceptibility to 28 IL10
Sources

Anatomical Context for Graft-Versus-Host Disease

About this section

Organs/tissues related to Graft-Versus-Host Disease:

MalaCards : Bone Marrow, Bone, T Cells, Liver, Myeloid, Eye, Skin
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Graft-Versus-Host Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
Sources

Publications for Graft-Versus-Host Disease

About this section

Articles related to Graft-Versus-Host Disease:

(show top 50) (show all 29987)
# Title Authors PMID Year
1
Genetics of risk factors for graft-versus-host disease. 53 62 57
16412785 2006
2
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. 53 62 57
14657427 2003
3
A protective gene for graft-versus-host disease. 62 57
14657422 2003
4
Mapping of the human IL10 gene and further characterization of the 5' flanking sequence. 57
9162098 1997
5
Chemokine receptor CCR5 mediates alloimmune responses in graft-versus-host disease. 53 62
20025985 2010
6
Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease. 53 62
19965675 2010
7
Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. 53 62
20160060 2010
8
CCR5 expression on cells from HLA-matched unrelated marrow donors and graft-versus-host disease. 53 62
20053336 2010
9
Soluble lymphotoxin is an important effector molecule in GVHD and GVL. 53 62
19789388 2010
10
Expression of CD62L on donor CD4(+) T cells in allografts: correlation with graft-versus-host disease after unmanipulated allogeneic blood and marrow transplantation. 53 62
19462221 2009
11
Association of IL-10 and IL-10Rbeta gene polymorphisms with graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling donor. 53 62
19409109 2009
12
High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults. 53 62
19159415 2009
13
Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. 53 62
19221040 2009
14
Ex vivo inhibition of NF-kappaB signaling in alloreactive T-cells prevents graft-versus-host disease. 53 62
19260829 2009
15
Donor treatment with a multipegylated G-CSF maximizes graft-versus-leukemia effects. 53 62
19135951 2009
16
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. 53 62
18614760 2008
17
Plasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients. 53 62
18541194 2008
18
Extracorporeal photopheresis affects co-stimulatory molecule expression and interleukin-10 production by dendritic cells in graft-versus-host disease patients. 53 62
18234053 2008
19
Interleukin-10 gene polymorphism in bone marrow transplant recipients. 53 62
18405249 2008
20
[Donor lymphocyte infusion for treatment of relapse of leukemia after HLA-mismatched hematopoietic stem cell transplantation]. 53 62
18681305 2008
21
PECAM-1 polymorphism affects monocyte adhesion to endothelial cells. 53 62
18301339 2008
22
Importance of interleukin-7 in the development of experimental graft-versus-host disease. 53 62
18158957 2008
23
IL2 and TNFA gene polymorphisms and the risk of graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. 53 62
18021367 2007
24
Single nucleotide polymorphism of CC chemokine ligand 5 promoter gene in recipients may predict the risk of chronic graft-versus-host disease and its severity after allogeneic transplantation. 53 62
17984846 2007
25
Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. 53 62
17889355 2007
26
Absence of cutaneous TNFalpha-producing CD4+ T cells and TNFalpha may allow for fibrosis rather than epithelial cytotoxicity in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. 53 62
17429441 2007
27
Granulocyte colony-stimulating factor for the induction of T-cell tolerance. 53 62
17632408 2007
28
A single minor histocompatibility antigen encoded by UGT2B17 and presented by human leukocyte antigen-A*2902 and -B*4403. 53 62
17496542 2007
29
Expression of CCR5 in graft-versus-host disease (GVHD) of the skin: immunohistochemical staining of 38 cases. 53 62
17352723 2007
30
Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. 53 62
17331846 2007
31
Influence of killer cell immunoglobulin-like receptor genotypes on acute graft-vs-host disease after unrelated hematopoietic stem cell transplantation in Koreans. 53 62
17445182 2007
32
Kappa immunoglobulin light chain polymorphisms and survival after allogeneic transplantation for B-cell malignancies: a potential graft-vs-leukaemia target. 53 62
17212708 2007
33
Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. 53 62
16937391 2007
34
Interleukin-18 and the pathogenesis of inflammatory diseases. 53 62
17336692 2007
35
CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. 53 62
17145599 2006
36
Role of non-HLA genetic polymorphisms in graft-versus-host disease after haematopoietic stem cell transplantation. 53 62
16984283 2006
37
The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. 53 62
16864058 2006
38
Effect of interleukin-15 on alloreactivity in umbilical cord blood. 53 62
16860714 2006
39
DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens. 53 62
16707472 2006
40
No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF. 53 62
16646673 2006
41
Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. 53 62
16123384 2006
42
Genomic polymorphism and allogeneic hematopoietic transplantation outcome. 53 62
16399580 2006
43
Daclizumab for children with corticosteroid refractory graft-versus-host disease. 53 62
16247417 2006
44
Expression of OX40 (CD134) on CD4+ T-cells from patients with myasthenia gravis. 53 62
16367941 2006
45
Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation. 53 62
16413397 2006
46
Cytokine-mediated signalling and early defects in lymphoid development. 53 62
16264332 2005
47
Simultaneous control of third-degree graft-versus-host disease and prevention of recurrence of juvenile myelomonocytic leukemia (JMML) with 6-mercaptopurine following fulminant JMML relapse early after KIR-mismatched bone marrow transplantation. 53 62
16344675 2005
48
Interleukin-18 treatment options for inflammatory diseases. 53 62
20477603 2005
49
The association of CD25 expression on donor CD8+ and CD4+ T cells with graft-versus-host disease after donor lymphocyte infusions. 53 62
16219576 2005
50
IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease. 53 62
15976176 2005
Sources

Variations for Graft-Versus-Host Disease

About this section

Copy number variations for Graft-Versus-Host Disease from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 188553 4 66300000 70400000 Absence of gene UGT2B17 Graft versus host disease
Sources

Expression for Graft-Versus-Host Disease

About this section
Search GEO for disease gene expression data for Graft-Versus-Host Disease.
Sources

Pathways for Graft-Versus-Host Disease

About this section

Pathways related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Cytokine Signaling in Immune system 66
Show member pathways
 13.11 TNF IL2 IL10 IFNG CSF3
2
PAK Pathway 64
Show member pathways
 13.09 CSF3 IL10 IL2 MYO1G TNF
3
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.45 TNF IL2 IL10 IFNG
4
Immune response IL-23 signaling pathway 22
Show member pathways
 12.43 TNF IL2 IL10 IFNG
5
NF-kappaB Signaling 3
12.41 TNF IL2 IL10 IFNG
6
Immune response CD16 signaling in NK cells 22
Show member pathways
 12.04 TNF IL2 IFNG
7
T-cell activation SARS-CoV-2 74
Show member pathways
 12.01 TNF IL2 IL10 IFNG
8
Neuroinflammation and glutamatergic signaling 74
11.94 TNF IL10 IFNG
9
Spinal cord injury 74
11.85 TNF IL2 IFNG
10
IL27-mediated signaling events 61
Show member pathways
 11.78 TNF IL2 IL10 IFNG
11
Allograft rejection 74
11.73 TNF IL2 IL10 IFNG
12
Acute viral myocarditis 74
11.64 IL2 IL10 IFNG
13
Innate Lymphoid Cells Differentiation 65
11.64 IFNG IL10 IL2 TNF
14
Hematopoietic Stem Cells and Lineage-specific Markers 65
11.62 TNF IL2 IL10 IFNG CSF3
15
AP-1 transcription factor network 61
11.59 IL2 IL10 IFNG
16
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 61
Show member pathways
 11.57 TNF IL2 IFNG
17
Dendritic Cells Developmental Lineage Pathway 65
11.57 TNF IL2 IL10 IFNG
18
Photodynamic therapy-induced NF-kB survival signaling 74
Show member pathways
 11.53 IFNG IL2 TNF
19
Extrafollicular B cell activation by SARS-CoV-2 74
11.52 TNF IL2 IL10 IFNG
20
Interleukin-10 signaling 66
11.4 TNF IL10 CSF3
21
THC Differentiation Pathway 64
11.4 TNF IL2 IL10 IFNG
22
Inflammatory bowel disease signaling 74
Show member pathways
 11.39 TNF IL2 IL10 IFNG
23
Th2 Differentiation 65
11.38 IL2 IL10 IFNG
25
IL-10 Pathway 64
11.21 TNF IL10
26
Inflammatory response pathway 74
11.18 IL2 IFNG
27
Development and heterogeneity of the ILC family 74
11.16 TNF IFNG
28
IL-15 Signaling and its Primary Biological Effects in Different Immune Cell Types 65
Show member pathways
 11.11 TNF IL2 IL10 IFNG
29
OX40 Pathway 64
11.1 IL2 IL10 IFNG
30
Interactions of natural killer cells in pancreatic cancer 74
11.09 TNF IFNG
31
IL12 signaling mediated by STAT4 61
11.08 IL2 IFNG
32
G-protein signaling_Rap2B regulation pathway 22
10.84 TNF IL2 IL10 CSF3
33
Selective expression of chemokine receptors during T-cell polarization 74
10.8 IL2 IFNG
34
Immune infiltration in pancreatic cancer 74
10.69 TNF IL2 IL10 IFNG
35
RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) 66
10.61 IL2 IFNG
36
Cytokines and inflammatory response 74
10.48 TNF IL2 IL10 IFNG CSF3
Sources

GO Terms for Graft-Versus-Host Disease

About this section

Cellular components related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.44 TNF ITFG1 IL2 IL10 IFNG CSF3

Biological processes related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA-binding transcription factor activity GO:0051091 10.05 TNF IL10 CSF3
2 response to ethanol GO:0045471 10.01 TNF IL2 CSF3
3 positive regulation of inflammatory response GO:0050729 10 TNF IL2 IFNG
4 positive regulation of cytokine production GO:0001819 9.93 TNF IL10 IFNG
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.91 TNF IL2 IFNG
6 immune response GO:0006955 9.91 CSF3 IFNG IL10 IL2 TNF
7 positive regulation of amyloid-beta formation GO:1902004 9.89 TNF IFNG
8 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.88 TNF IFNG
9 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.87 TNF IL10
10 astrocyte activation GO:0048143 9.86 TNF IFNG
11 positive regulation of MHC class II biosynthetic process GO:0045348 9.85 IFNG IL10
12 positive regulation of signaling receptor activity GO:2000273 9.81 IL10 IFNG
13 endothelial cell apoptotic process GO:0072577 9.8 TNF IL10
14 negative regulation of amyloid-beta clearance GO:1900222 9.78 IFNG TNF
15 negative regulation of cytokine production involved in immune response GO:0002719 9.71 TNF IL10
16 positive regulation of plasma cell differentiation GO:1900100 9.62 IL2 IL10
17 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.56 TNF IFNG
18 positive regulation of nitrogen compound metabolic process GO:0051173 9.46 TNF IFNG
19 positive regulation of vitamin D biosynthetic process GO:0060557 9.26 TNF IFNG
20 chronic inflammatory response to antigenic stimulus GO:0002439 8.92 TNF IL10

Molecular functions related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.32 TNF IL2 IL10 IFNG CSF3
Sources

Sources for Graft-Versus-Host Disease

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....